Home > Newsletters > FDAnews Drug Daily Bulletin > FTC Conditions on Watson’s Actavis Acquisition Are Manageable: Analyst
FDAnews Drug Daily Bulletin
Nov. 6, 2012 | Vol. 9 No. 218
FTC Conditions on Watson’s Actavis Acquisition Are Manageable: Analyst
The FTC tentatively approved Watson Pharmaceuticals’ acquisition of Actavis, provided Watson transfers rights to 18 drugs to Sandoz and Par Pharmaceuticals and relinquishes manufacturing and marketing rights to three other products involved in the sale. The most significant divestitures require Watson to divest one version of each of the eight already marketed generics that are sold by both companies.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.